Ivermectin in Treatment of COVID-19

Use of Ivermectin as a Therapeutic Option for Patients With COVID-19

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04445311

Enrollment

100

Registered

2020-06-24

Start date

2020-05-31

Completion date

2020-08-15

Last updated

2020-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID

Brief summary

confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt

Interventions

DRUGIvermectin

3 successive days ttt of ivermectin started within 48 hours of symptoms

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

COVID-19 patients during period of the study more than 18 years old

Exclusion criteria

refuse to participate pregnancy or lactation hypersensitivity to ivermectin receive any drug with interaction with ivermectin

Design outcomes

Primary

Measure	Time frame	Description
time to be symptoms free	within 21 days after enrollment	duration from day 1 symptoms till 3 days without symptoms

Secondary

Measure	Time frame	Description
hospitalization	within 21 days after enrollement	need hospital admission
Mechanical ventilation	within 21 days after enrollement	need mechanical ventilation
length of stay	within one month days after enrollement	days spent in hospital
mortality	within one month days after enrollement	survived or died

Countries

Egypt

Contacts

Primary ContactWaheed Shouman, MD

shouman66@gmail.com+201114812048

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026